EW FY2026 Q2 RAISED

Отчётный звонок Edwards Lifesciences Corporation

Jul 23, 2026 · 13:00 ET Bernard ZovighianDaveen ChopraDoretta Mistras

Вывод Buzzberg

Full-year sales guidance raised to 10-11%

Edwards Lifesciences reported a strong Q2 2026 beat, raised full-year guidance across TAVR, TMTT, and total company, and maintained EPS outlook despite tax headwinds. Management highlighted sustained market share gains, robust TMTT portfolio growth (Pascal, Evoque, Sapien M3), and upcoming catalysts including Progress trial data and US NCD finalization. Total company revenue $1.74B (+12.5% y/y) beat expectations; TAVR $1.3B (+10.5%), TMTT $195.9M (+44.8%).

Вывод Buzzberg Full-year sales guidance raised to 10-11% Edwards Lifesciences reported a strong Q2 2026 beat, raised full-year guidance across TAVR, TMTT, and total company, and maintained EPS outlook despite tax headwinds. Management highlighted sustained market share gains, robust TMTT portfolio growth (Pascal, Evoque, Sapien M3), and upcoming catalysts including Progress trial data and US NCD finalization. Total company revenue $1.74B (+12.5% y/y) beat expectations; TAVR $1.3B (+10.5%), TMTT $195.9M (+44.8%). Читать полный анализСвернуть анализ

FY2026 total revenue guidance raised to 10-11% growth ($6.6-6.9B); TAVR to 8-9% ($4.75-5B); TMTT to $760-780M.
Adjusted EPS guidance maintained at $2.95-$3.05 despite tax headwinds (higher effective rate).
Q3 2026 guided to $1.63-1.71B revenue and $0.71-0.77 EPS, reflecting higher prior-year comps.

TAVR revenue $1.3B +8% QoQ

TMTT revenue $0.1959B +13% QoQ

Revenue $1.741B +6% QoQ

EPS $0.78 +0% QoQ

Что изменилось в этом квартале

Guidance

Full-year sales guidance raised to 10-11%

Guidance · revenue to $6.75B

Demand

TMTT revenue grew 44.8% year-over-year

Management expressed strong confidence driven by better-than-expected Q2 results, raised full-year guidance, and reiterated long-term growth targets, reflecting a notably upbeat tone.

Demand

TAVR global sales up 10.5% to $1.3B

TMTT revenue grew 44.8% year-over-year. Management expressed strong confidence driven by better-than-expected Q2 results, raised full-year guidance, and reiterated long-term growth targets, reflecting a notably upbeat tone.

Demand

Growth benefited from competitor exit in Q2 2025

Спрос и капзатраты

Спрос

Заказы и конверсия

Капзатраты

Инвестиции и мощности

Management stated that their highest capital allocation priority is investing in organic growth and strengthening the manufacturing network, with ongoing investment in the business supporting operating margin expansion.

Тон · confident

Management expressed strong confidence driven by better-than-expected Q2 results, raised full-year guidance, and reiterated long-term growth targets, reflecting a notably upbeat tone.

Прогноз компании

RaisedGuidance · revenue to $6.75B

Прогноз компании
Показатель	Период	Диапазон	Середина	Статус
EPS	FY2026	$2.95–$3.05	$3.00	MAINTAINED
EPS	FY2026 Q3	$0.71–$0.77	$0.74	GUIDED
Revenue	FY2026	$6.6B–$6.9B	$6.75B	RAISED
RevenueTAVR	FY2026	$4.75B–$5B	$4.875B	RAISED
RevenueTMTT	FY2026	$0.76B–$0.78B	$0.77B	RAISED
Revenue	FY2026 Q3	$1.63B–$1.71B	$1.67B	GUIDED

Надёжность прогнозов

6 / 6выполнено или превышено

Надёжность прогнозов
Дата прогноза	Показатель	Целевой период	Прогноз	Факт	Результат
FY2026 Q1	EPS	FY2026 Q2	$0.70–$0.76	$0.78	Met / beat
FY2026 Q1	Revenue	FY2026 Q2	$1.66B–$1.74B	$1.741B	Met / beat
FY2025 Q4	EPS	FY2026 Q1	$0.70–$0.76	$0.78	Met / beat
FY2025 Q4	Revenue	FY2026 Q1	$1.55B–$1.63B	$1.6486B	Met / beat
FY2025 Q3	EPS	FY2025 Q4	$0.58–$0.64	$0.58	Met / beat
FY2025 Q3	Revenue	FY2025 Q4	$1.51B–$1.59B	$1.5696B	Met / beat